PMID: 8609278Mar 1, 1996Paper

The outcomes movement and new measures of the severity of psoriasis

Journal of the American Academy of Dermatology
K E McKenna, R S Stern

Abstract

Traditionally physicians have assessed the severity of psoriasis on the basis of involved surface area or other physical features. These measures are not highly reliable and do not quantify the extent to which the disease affects the patient. New approaches to health care assessment have been developed, including evaluation of the outcome of medical care. This new direction in health care assessment has been described as the "outcomes movement." This emphasizes the assessment of patients' outcomes with respect to quality of life and functional capacity, rather than traditional techniques that rely on the results of physical or laboratory examinations. New measures to assess treatment effectiveness will almost certainly be used to allocate health care resources. We review the status of measures of psoriasis and the implications of newer methods for assessing disease impact and outcomes of therapy.

References

Jan 1, 1978·Dermatologica·T Fredriksson, U Pettersson
Nov 1, 1977·Rheumatology and Rehabilitation·P J Scott, E C Huskisson
Sep 1, 1976·Clinical and Experimental Dermatology·R G Jobling
Feb 1, 1992·The British Journal of Dermatology·P C van de Kerkhof
Jul 1, 1992·The British Journal of Dermatology·P M McHenry, V R Doherty
Jul 1, 1991·The British Journal of Dermatology·A G QuinnP M Farr
Jun 1, 1991·The British Journal of Dermatology·B Ramsay, C M Lawrence
Jan 1, 1990·Annual Review of Public Health·D L Patrick, M Bergner
Dec 1, 1990·The British Journal of Dermatology·A Y FinlayM S Salek
Jul 26, 1990·The New England Journal of Medicine·A M Epstein
Jan 1, 1989·Journal of the American Academy of Dermatology·I H Ginsburg, B G Link
Jan 1, 1985·Social Science & Medicine·S Jowett, T Ryan
Nov 3, 1988·The New England Journal of Medicine·A S Relman
Feb 1, 1988·The British Journal of Dermatology·B Ramsay, M O'Reagan
May 1, 1986·Journal of the American Academy of Dermatology·F S Glickman
Sep 1, 1986·Journal of the American Academy of Dermatology·R S SternJ A Parrish
Jan 1, 1987·Clinical and Experimental Dermatology·A Y Finlay, S E Kelly
May 1, 1986·Journal of the American Academy of Dermatology·N J LoweL S Moy
May 1, 1986·The British Journal of Dermatology·C M LawrenceS Shuster
Aug 1, 1973·Archives of Dermatology·H M Robinson
Feb 1, 1980·Arthritis and Rheumatism·R F MeenanJ H Mason
Aug 24, 1994·JAMA : the Journal of the American Medical Association·T M Gill, A R Feinstein
Jan 1, 1994·Dermatology : International Journal for Clinical and Investigative Dermatology·S RootM S al-Abadie

❮ Previous
Next ❯

Citations

Feb 9, 2005·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·I ZschockeM Augustin
Mar 22, 2005·Journal of Cutaneous Medicine and Surgery·D R Thomas
May 16, 2006·Journal of Cutaneous Medicine and Surgery·Kim A Papp, Eric Henninger
Jun 19, 1998·Journal of the American Academy of Dermatology·H B Faust
Jan 6, 1999·Journal of Clinical Pharmacy and Therapeutics·D M AshcroftC E Griffiths
Nov 8, 2002·Journal of Evaluation in Clinical Practice·Steven J ErsserAnne Wiles
Nov 9, 2002·The Australasian Journal of Dermatology·Nicole JennerRobin Marks
Mar 1, 1997·The British Journal of Dermatology·A Y Finlay
Feb 15, 2005·Annals of the Rheumatic Diseases·L S WinterfieldA Gottlieb
Sep 21, 2006·BMC Dermatology·Kim A Papp, Eric Henninger
Apr 17, 2004·The Journal of Investigative Dermatology·Francesca SampognaUNKNOWN IDI Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) Investigators
Apr 16, 2004·The Journal of Investigative Dermatology. Symposium Proceedings·John de KorteJan D Bos
May 27, 2009·Journal of the American Academy of Dermatology·Elizabeth FarleyAlan Menter
May 13, 2005·The British Journal of Dermatology·A Y Finlay
Jan 13, 2006·Journal of the European Academy of Dermatology and Venereology : JEADV·K OngenaeJ-M Naeyaert
Nov 29, 2005·Clinical and Experimental Dermatology·H B Hahn, T-Y Chuang
Sep 27, 2007·Journal of the European Academy of Dermatology and Venereology : JEADV·A FinziUNKNOWN PSYCHAE Study Group
Sep 25, 2004·Journal of the American Academy of Dermatology·Richard G Langley, Charles N Ellis
Jul 1, 1997·Journal of the American Academy of Dermatology·R T Anderson, R Rajagopalan
Oct 31, 1997·Journal of the American Academy of Dermatology·S R FeldmanA R Clark
Aug 26, 2004·The British Journal of Dermatology·C C Jacobson, A B Kimball
May 13, 2005·The British Journal of Dermatology·S S ZaghloulM J D Goodfield
Nov 9, 2005·Journal of the European Academy of Dermatology and Venereology : JEADV·S FouéréH Pawin
Sep 30, 2009·The British Journal of Dermatology·L NaldiUNKNOWN European Dermato-Epidemiology Network
Feb 15, 2012·Journal of the European Academy of Dermatology and Venereology : JEADV·D BöhmG Schmid-Ott
Mar 7, 2012·The Journal of Dermatological Treatment·Shiu-Chung AuAlice B Gottlieb
Jan 25, 2011·The Journal of Dermatological Treatment·Hsien-Chang LinRajesh Balkrishnan
Oct 26, 2000·Journal of the American Academy of Dermatology·E VenselJ B Schwartzberg
May 22, 2004·Journal of the American Academy of Dermatology·Christopher S CarlinGerald G Krueger
Oct 4, 2007·Dermatology : International Journal for Clinical and Investigative Dermatology·Luigi Naldi
Aug 15, 2001·The British Journal of Dermatology·L H de Arruda, A P De Moraes
Jul 25, 2008·The Journal of Dermatological Treatment·Amit S KulkarniSteven Feldman
Oct 3, 2003·The Journal of Dermatological Treatment·S WeismanR W Gottschalk
Nov 9, 2000·The British Journal of Dermatology·R J TurnerP M Farr
Dec 22, 1998·Seminars in Cutaneous Medicine and Surgery·A Y Finlay

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Pharmacy and Therapeutics
D M AshcroftC E Griffiths
Clinical and Experimental Dermatology
G Kent, M S al-Abadie
BMJ : British Medical Journal
R J TurnerD Walshaw
© 2021 Meta ULC. All rights reserved